HUE033392T2 - Immunmodulációs progenior (IMP) sejt - Google Patents

Immunmodulációs progenior (IMP) sejt Download PDF

Info

Publication number
HUE033392T2
HUE033392T2 HUE15729886A HUE15729886A HUE033392T2 HU E033392 T2 HUE033392 T2 HU E033392T2 HU E15729886 A HUE15729886 A HU E15729886A HU E15729886 A HUE15729886 A HU E15729886A HU E033392 T2 HUE033392 T2 HU E033392T2
Authority
HU
Hungary
Prior art keywords
cells
population
imp
patient
iii
Prior art date
Application number
HUE15729886A
Other languages
English (en)
Inventor
Ajan Reginald
Martin John Evans
Sabena Sultan
Original Assignee
Cell Therapy Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapy Ltd filed Critical Cell Therapy Ltd
Publication of HUE033392T2 publication Critical patent/HUE033392T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0633—Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/115—Platelets, megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)

Claims (1)

  1. SMMÜNMOOUUCrôS PROQESIOR {MP} SEJT SZABMMJ» K5ÉWPONTOK 1 tttmtftooáMto* pMP; *# ate a k«wW»*ô nrseany«^^ a tetssz a kévető fehé$*&amp;t: MSf": m> 05304 {Miteepie 1 !. COI ?8 (FAS-llgandem): Cmm (îetlteem receptor 0}, CÖ» {S/tli-goai*-\4miàï receptor 1 h o:h' 'pte i*iuvOn.^ >. tej·-* te ί *. e* ' -ts ^ ' sf ' ' ' r,>t 4 5 V,.-..; e> 0012¾ ;;22;Â: fa} aa #P eap ^ ##Ä-ÄiP#Ä ÄlÄÄ i $PP§ jspiem -, gytedáetekksetá· hatást fejtsen k bteagy ektexplse a? ang-agenete; s'b| ai iMP sett; képes anas hogy :a ééísgpen sgy tegbafteaes sere·! steames: ^ivansorc-pn s vasïkmaes endsmekebtea teaste, (q iMF sejt képes arra, hogy s betegbe* séféit ete *seeb: pote te saaiag-* màp, vese- vagy têdésteatem vsndsrette. hezsábip^iiem vágy gyiá lltP sajt képes ana, hogy a betegben àtenteete a vasstebs enstóheiíymon hemstel a sete ste. oson?· pme·. te sxstete mái-, vese- vagy îedoszovethez. í3<:A Ί «ig? a 2, sgéaypte astete; IMP sajt, apót: {â! sa tyP seg képes in tem módón tetetem sói* saisé dt§éíass«á\tem (5)02 IMP seif aatotóg sag? aitegtekus seit, es/sagy (ei sa IMP sett te Wm vagstes« módén gyógyászáé és/vagy àtegnosteikat hatóanyaggal terheit vsey teltette : 4 $£MW jpéaypoálh:Mrma|iké säis; Mliysff tâté MH$$lf0P®$0ß>.··· 4 temms;*oteéstes progselks {édite sejtek populáteéja. slKk fi) a popÄ-sö sejtjamek. legalább éôâtea e.te'esszte a Nsü§ ' $$4» (it! a popÄKj sastlemek legalább feb%-a e.teesezái a létemén klmteamstó rnshay-ségű CD504-&amp;I iteemopten 1), (lüí a popteéte sajíjeteek legalább *5%·* eteasste a te slabs temteateate teanytegd CDt/é-ai oteASiigandurte. {ΐνΐ a poéolsdö setééinek legalább "0% s éxp^steà a telakteèp ktesutatbaié mennyiségű CD2S9-«t (Tolbezerd remploi' §;·. {V) a papntâctô tegatabb 15¾¾-a expsessïâi a leisteten temalamaîo mennyssógd C0383-aî (Stetegmnn 1 testét recepter H sejtjeinek legalább 20%·« expmssgáléleteaéb klmataiálé nieneyiaégü CD2^-ap {vsi} a pepoteP sejtjemek legailfeb löü-é ékptsaséi ia í^ípÉb Opl|l#tt {:íte; Nf'v^f roce, s, sikk {«O a popeteié sütete kgkàéb 30k-a e>:p?as&amp;?ai a fstssaiéa kimaîaSéstd mímnymégá emdeaaáka a éve Sites; takte nteptet (cGF-k) î>ï) a piteáclo sepiSiite ift-g^abb 60'*-« s<.p!aessat a talas nan kamtete .'pena>'isegu CéCP2-p ix) a ppkéslêçteeejtâetek legalább 5%-á ëâps^x^ a îeisslaéa klteteihem menra/tepu CDI 2a·*; |.Ä* îgènypoat s?enntiteïpaiàd6. «hol :fi: if* a populáció suiliOuíik RgPDbb 8?% -a íxpóíimót s lelsarifs^n ksrnutaihatö muasyiséíd M=C A/8-t íiii a populáció sciOsinsk teosióbb CSx-a expicscyè; a ieKamán fesn-utsîhaîo msocyiségà OD334 -ai (Nçurop»·'^ U-m a populáció it^íüXsk lagalább 51X -a a.\o;&amp;wôi a ietenX; RPHPothato mcoapsáp CD 1 ?$ at (FAS-Sga·^^}. i-v) a populáció sajfjeiaeK isgaiabo 11 %&amp; emiw^M -s farinán k-^-naibato rfanny^gû Cj2§8sï (Toit ssan'j tacsp*^ ÿi. ív; a populáció iagalâbb 1θ%·δ (v'C 8 populáció áajtjáiPák iogalèbo 2.4%-s exprsssxèi a fciax^èc saí^aíasiató aiaaay^gy CObS-al, {y;·; a populáció pcdo^ak îpgslàbo S^%-a axprassïàî kiuwtaibalô maanyiaègù Cf.>181^t(Cv4üR?|, i'viiíj a pppuïàoô sejtenék t&amp;gaîâàb 33ivs expiasses' kanytatkatb uiaucyisàgù pp^s-pt«·« f ov-xadss! isMof uRoP^' s«+- ïil àx) a populace- sultjeiueh lapalabb 68%-a axpi-uss^i klmutatpato fftöPayiSégO CXCR%i as (x) a populáció sajtjwsk ispa58bh ?%-ss esfpiessaâi kiCsubXbalo touncylsopü CDDi'-o?. (P; a popuîàoP s%Sao<?k %p%;% 80%-a spasms s iaRdoôo xiasuX-lbatâ soauoyisépPsi; «x dabui n0.üX «4?y« tPbbat vagy micdogylkei CDf0?:: ôlt^:, CD28? &amp;M% 00273. CQ5f;CD6C CD48Í. CD49P, CD 146. &amp;£§&amp;; OP34g. CDbl. CD17Ss. CD82, CD4Sb. CD85, CD63, CD24S CD3&amp; CD138. 82-xnikicgîpiXiisn. CDi 53. CD2S8îO©44: C.D43c, CUlOb CD16C. CD230 rlA-ABC CDt3 CD29. CD49s, CDS3. CD?3. CD&amp;1. CDS0; CD9S. CD14?. ODISf ás G02?s> M s p^si^â ssîlêioek löpiáisb :8C%íg s^smM a feicalbâc xkaoiatPÄ iïsamsyssésgfeef» «4 âÜ tsbbst vagy sOßäeg^acer- <^ïëe%'-ÉI3æâ;;^Ôt2^âi==i^a Ιϊΐ^θβ. CD33X $C£A-4. C0348 ss CD140P. (p: a populace seji}elP6k legalább ?ö%.« expulsai 8 fctsxfuèa kimalatbafó ixiennyssápcb m síspIíí labáijáx ^ ^yAu i&amp;bóí vagy hegyiket- CD'M, C0351. CDM CD48. CDi 18 és CC132;: (pi 3 populáció PPlseiPey 1%*8 vagy $*t$ kevesebb» fejsén kiciutaihsio a?, s&amp;bto fwssqe* xoxu· ^ <%ΓίΓ „ %y v-< f"\ 00 %> Of \ 35 0 0¾ *"' i ' 0' ^ vló '^ϊ α CD?3f 'T^v^ OOÔ-î CCc'· CIV/λ OfV ? bt 004ó 0Λ'"Γ i Γ Di '3Γ0 OL'F 0D4 ' ΟΛΓο 00; 0' ft CfVD·’ CLV OO'v/ »'.AOM (>^f \* 1 0"'' 0'*N,< ' ».S V"' ' N 00 C>”'U ! ' •·,δ0184. CDtOTb CD138, CD? CDSO hU-DR. CDiőSox. CÖb^. DCiR. CD4S. CLA. CD3§- CD4£R8. CD34. Oütbl. C02.; 530418, CDb2, CD13Ù CQC28, TOR Óla béta, CQIbb CD1s, RC80 CD1á4; CD?ö. CDxíxIBb, CD13/, 0043, 0030 0^^ 0033 CD38: CDI óik CDÖb. CD212. CDI??, CB142. CD15?. CD352. CD4Sa, CD33Ô. 0024a. CD4a. CD4:jR^, ‘~0<u-u, CD2Ö0, CD22, CDHC. CD28. 0018, 0021 CD33S: CD131. CD32. CDfb?. C01S5, CDl3?a «χΙΡ, ^uàü. wlöO ős CD24; sgénypofit sïewiH í^sjűouságokkai w^e^e&amp;^gy ^ ^ ? r«*s,i rntmm. *m w*« w » 1-1 W- —* ap *** *»3 ** ^,5afc‘ ' « HwfftiaSs -0,.^· »** -» ^ «i8ä> SbS9ÄSSi' fegy vapy iôbb mskiPbPboyêkcf. .· ·<χ·'»ί< juí.44iííiá«i«s iîhôi a n'ôPsiar a kovatxcxbxpbi à« (p :%·:ψφί*** s 4-8. íaényboatok biamatyika y?e?«ia IMA &amp;atax -.......... . A. . v “ ' , .... ,.ár^..^8.i:/í>5ufnot t«i?öarsaaö taptaiisOä>, kO^-ná; ír-ofv^uRuáfáí sópek (MG-k) Ipnvèsrièsa 15-23 ^apoa Ksra?i>«í ........ ..... . , -...... ., . , „ jftC-»sfc ρ,·Χ5ν ax M? ceitcx fuac-apdiaaax as oxipúii fÖí) üÄH fcs i>iv«s köföinaeoyí* ko.íob. a8«^ *-"............... h v ' . . . ; .......-.triiC â' ÎN;> 'í::yia5:;;sk a öSgysiOxa SS tanyiSkió&amp;a. Μ» « MM » «HM rn«*» >« — ' ... . , . , ' -x. Äi a ía k^ypós^ síopulaob ^jyek 3í t î^î^wî *tw* íxpress^te ^äk es - ^ ' ''">!' afosStax-a. ΐί. A 8. igénypont szinti m&amp;Asssn ahol: la) m Iá) a? bföA^afy bai^bâi:^ égy sii%nisysaï^^ 10 A ·*-·5 ^«ηη^οΚ Oâ-T aA'isa xrw pcwaoA cox a -’ νό^ρ,νν ivxnm» gyugvusauti \0s* am'*'y ?"U.a s^vh Nk'aaiaa?* ÉÜaéféfeeíi Ä:ÄÄIÄt:^:ħöfeaty S:.ÄÄ pro,, in·, sxai^iMas|| ^sAAaif-iâdl #miés#b<É Ä#i eaaé? éOsa -#1è ÄssfifÄ·^ Ägnl* 11 ; iÜ AÔÉÂIÔ: ^:::1:^ (!) a sémii iAÄ s:iiëaoaêfmibll saAmask; (ii; s $èm saóvei a.dv-. esögfx AÖii-A5'^IÍ3É>::0^\ (si;) a szov%!$éfú*s? sabesíiié* vagy balisée okosig vagy ό) g sïivsèfÿ^ vagy i.civbe&amp;gsôg 8 vovattegök kôpui v$aszsott. ηχΑδΑΐ^ΐΐε kvark&amp;x oa: Kamra! aipafU'óaa. -abb kamra.· hïpsrfiôiùi sîîvet^iensè^. veä&amp;aäfete« vAvmaay, s*iv$$sRtyú-feet%os%g, aatmsa as szsvriomgyu^a* &amp;&amp;ν$ψ·ρ· populációt ο balogból vagy agy ailogonAus donoitdi oyast M€-k iamaiznodsa&amp;vOi &amp;o. vagy ξκ) 3 cson&amp;àrOiès vagy cacvvoategí.sg a kovaikevok koala váiacxoto kxaa, Uailar-Hams-rsi« kirss. aokäg&amp;aydcre^, csoatayuívány. kcvmoaAcCiSSibkis, AcAa-lowcy sAockoma, progussoaivan íkosemosoPo bbaxasapiaaiis Oomsvs «semsea, m? x&amp;xa-pMM vhűm®)' h^ssíato: **m-m viaöröma. rs«?afcöi^$ «omlxaagsag kôrorm paSeba giindroma. osfesMhstis. osisAs döfcrmaRS lyagy a «ooi Hagai-aôça}. »Orcavs cvk.tas csaatgyuKadas ;vagy äbtosa vagy a csont von AacKiingbavsan-Kopaí. skemermvcsoni gyalfcoas-s, kondaaaaio csonigyuiiadào (vagy osfeus cor^sm), <5$*NUs eorcterw a. cataecncadnm. <?i$sec«n&amp;. »steogonsss ímpsrísaa. oaioomsisas. ost^y^V·. owat« csoaíH&amp;i^ «^ameHré^. p^c sis-xfeysa *yW?amy?<skii*n. vastagság V f a·, «^Μν’ 'V ' .ax o^c a xv-xvva*'o a *' ? vC**3~ *"'* v* ?,','rK% P^!Odomaife ősiéig ai i^eî» ptc&amp;fmk «sz^us «®8 * ^tegbô> vagy agy Nlbssoiôsâîvakaii |ak si#... U A fO fénypont «a**. popaiàoO a 10. vagya 11. :génypon? tM fe-sasznâSs«, &amp;* a pop«i**a a buteoixa vagy egy aip|afrilu|idfng?bôï nytsAAiy>A felhbSiiiáláOáyalAiiíigK
HUE15729886A 2014-06-12 2015-06-09 Immunmodulációs progenior (IMP) sejt HUE033392T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1410504.3A GB201410504D0 (en) 2014-06-12 2014-06-12 Immuno-modulaltory progenitor (IMP) cell

Publications (1)

Publication Number Publication Date
HUE033392T2 true HUE033392T2 (hu) 2017-12-28

Family

ID=51266501

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15729886A HUE033392T2 (hu) 2014-06-12 2015-06-09 Immunmodulációs progenior (IMP) sejt

Country Status (24)

Country Link
US (2) US12029763B2 (hu)
EP (2) EP2984163B1 (hu)
JP (2) JP6185657B2 (hu)
KR (2) KR20160029092A (hu)
CN (1) CN105473711A (hu)
AU (1) AU2015273271B2 (hu)
CA (1) CA2951492C (hu)
CY (1) CY1119093T1 (hu)
DK (1) DK2984163T3 (hu)
EA (1) EA034083B1 (hu)
ES (1) ES2622397T3 (hu)
GB (1) GB201410504D0 (hu)
HK (1) HK1219504A1 (hu)
HR (1) HRP20170657T1 (hu)
HU (1) HUE033392T2 (hu)
IL (2) IL249298B (hu)
LT (1) LT2984163T (hu)
MA (1) MA38860B1 (hu)
MY (1) MY181994A (hu)
PL (1) PL2984163T3 (hu)
PT (1) PT2984163T (hu)
SG (1) SG11201610355PA (hu)
WO (1) WO2015189587A1 (hu)
ZA (1) ZA201608402B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201513996D0 (en) * 2015-08-07 2015-09-23 Cell Therapy Ltd Immuno-oncology mesodermal progenitor (IOMP) cell
WO2017168170A1 (en) * 2016-03-31 2017-10-05 Cell Therapy Limited Immuno-modulatory progenitor (imp) cell expressing one or more of cd3, cd3e, cd8, cd8b, cd4, cd5, cd6 and cd7
JP7108537B2 (ja) * 2016-04-27 2022-07-28 ロート製薬株式会社 Ｃｄ２０１、ｃｄ４６、ｃｄ５６、ｃｄ１４７及びｃｄ１６５からなる群より選択される少なくとも１種の細胞表面マーカーを発現する間葉系幹細胞及びその調製方法、並びに上記間葉系幹細胞を含む医薬組成物及びその調製方法
CN106267161A (zh) * 2016-09-30 2017-01-04 广州赛莱拉干细胞科技股份有限公司 一种干细胞制剂及其制备方法和应用
CN107184602B (zh) * 2017-06-01 2020-06-30 刘未斌 一种治疗肿瘤的药物组合
WO2019013279A1 (ja) * 2017-07-13 2019-01-17 国立大学法人 東京医科歯科大学 三次元メカノシグナル細胞培養系を用いて作製した腱／靱帯様人工組織
CN108660203A (zh) * 2018-05-18 2018-10-16 大连医科大学附属第医院 Cxcr2基因在心脏相关疾病中的用途
TWI807036B (zh) * 2018-05-30 2023-07-01 南韓商韓國億諾生物有限公司 用於預防或治療癌症之包含作為活性成分之cd300e抑制劑的藥學組成物
AU2019283518A1 (en) * 2018-06-05 2021-01-14 Medipost Co., Ltd. Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease
GB201900554D0 (en) 2019-01-15 2019-03-06 Cell Therapy Ltd Mesodermal killer (mk) cell
US20230047325A1 (en) 2019-01-15 2023-02-16 Cell Therapy Limited Mesodermal killer (mk) cell
CN110314173A (zh) * 2019-07-17 2019-10-11 中国医科大学附属第一医院 一种用于治疗骨关节炎的细胞制剂及其制备方法
WO2021092564A1 (en) * 2019-11-07 2021-05-14 Massachusetts Eye And Ear Infirmary Cultivated autologous limbal epithelial cell (calec) transplantation
WO2024080661A1 (ko) * 2022-10-12 2024-04-18 (주) 엘피스셀테라퓨틱스 신규한 혈관 형성 줄기세포
WO2024078729A1 (en) * 2022-10-14 2024-04-18 University College Cork - National University Of Ireland, Cork Placenta expressed proteins for use in the treatment of tendon injury

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801537D0 (sv) 1988-04-26 1988-04-26 Ellco Food Ab Cellodlingsmedium samt forfarande for dess framstellning
WO2009144718A1 (en) 2008-05-28 2009-12-03 Ramot At Tel Aviv University Ltd. Mesenchymal stem cells for the treatment of cns diseases
US20110123498A1 (en) 2009-10-30 2011-05-26 Christof Westenfelder Mesenchymal stromal cell populations and methods of using same
EP2506867B1 (en) * 2009-12-02 2014-10-08 Cardio3 Biosciences S.A. Pharmaceutical compositions for the stimulation of stem cells.
US20130189741A1 (en) * 2009-12-07 2013-07-25 Cellscript, Inc. Compositions and methods for reprogramming mammalian cells
WO2012052911A1 (en) 2010-10-22 2012-04-26 Nokia Corporation Method and apparatus for co-operative reception for network controlled device to device
EA029577B1 (ru) 2011-07-06 2018-04-30 Селл Терапи Лимитед Клетки-предшественники мезодермальной линии
CA2856642C (en) 2011-11-23 2019-09-17 Cell Therapy Limited Platelet lysate gel
US9682104B2 (en) * 2012-01-26 2017-06-20 Jadi Cell Llc Lyophilized platelet lysates
US9670457B2 (en) 2012-05-08 2017-06-06 Stem Cell Reserve Lp Stem cells and matrix from cord tissue

Also Published As

Publication number Publication date
CN105473711A (zh) 2016-04-06
SG11201610355PA (en) 2017-01-27
ZA201608402B (en) 2019-04-24
IL249298B (en) 2018-11-29
LT2984163T (lt) 2017-05-10
PT2984163T (pt) 2017-05-09
EA034083B1 (ru) 2019-12-25
CA2951492C (en) 2022-12-06
ES2622397T3 (es) 2017-07-06
JP2017200474A (ja) 2017-11-09
AU2015273271B2 (en) 2020-12-17
IL249298A0 (en) 2017-02-28
WO2015189587A1 (en) 2015-12-17
MA38860B1 (fr) 2017-09-29
HRP20170657T1 (hr) 2017-06-30
EP2984163A1 (en) 2016-02-17
KR20160029092A (ko) 2016-03-14
EA201692254A1 (ru) 2017-06-30
IL262827A (en) 2018-12-31
PL2984163T3 (pl) 2017-08-31
CY1119093T1 (el) 2018-01-10
NZ727129A (en) 2021-02-26
US12029763B2 (en) 2024-07-09
DK2984163T3 (en) 2017-05-08
GB201410504D0 (en) 2014-07-30
JP6185657B2 (ja) 2017-08-23
EP3211069A1 (en) 2017-08-30
AU2015273271A1 (en) 2016-12-22
JP2016525342A (ja) 2016-08-25
HK1219504A1 (zh) 2017-04-07
KR20180004319A (ko) 2018-01-10
CA2951492A1 (en) 2015-12-17
EP2984163B1 (en) 2017-02-01
MY181994A (en) 2021-01-18
US20170080029A1 (en) 2017-03-23
US20190142869A1 (en) 2019-05-16
MA38860A (fr) 2016-02-17

Similar Documents

Publication Publication Date Title
DK2984163T3 (en) IMMUNMODULATORY PROGENITOR (IMP) CELL
US10829739B2 (en) Progenitor cells of mesodermal lineage
US20170119930A1 (en) Hybrid composition
US10316291B2 (en) Immuno-oncology mesodermal progenitor (ioMP) cell
WO2017168170A1 (en) Immuno-modulatory progenitor (imp) cell expressing one or more of cd3, cd3e, cd8, cd8b, cd4, cd5, cd6 and cd7
NZ727129B2 (en) Immuno-modulatory progenitor (imp) cell